

## Effects of Probiotic Soy Milk Fermented by *Lactobacillus plantarum* A7 (KC 355240) added with *Cuminum Cyminum* Essential Oil on Fasting Blood Glucose Levels, Serum Lipid Profile and Body Weight in Diabetic Wistar Rats

### Abstract

**Background:** There is some separate evidence that probiotic soy milk and *Cuminum cyminum* (*C. cyminum*) have positive effects on the prevention and reduction of diabetic complications. While the impact of probiotic soymilk mixed with herbal essential oils has not been investigated so far, the objective of this study is to examine the effects of probiotic soy milk using *Lactobacillus plantarum* A7 (KC 355240) added with essential oil of *C. cyminum* on diabetic rats.

**Methods:** 50 streptozotocin-nicotinamide (STZ-NA) induced diabetic Wistar rats were divided into five groups: Control group (C group), soy milk group (SM group), probiotic soy milk group (PSM group), soy milk containing essential oil of *C. cyminum* group (SMC group) and probiotic soy milk containing essential oil of *C. cyminum* group (PSMC group). The animals consumed these products (1 ml/day) for 30 days. The fasting blood glucose (FBS), the serum lipid levels, and body weight variation were analyzed in 10-day intervals. **Results:** FBS, total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) decreased significantly, whereas high-density lipoprotein cholesterol (HDL-C) increased in the PSMC group compared with that of other groups ( $P < 0.05$ ). This product also led to weight gain ( $P < 0.05$ ). **Conclusions:** A mixture of probiotic soy milk and herbal essential oil consumption could impose a positive effect on reducing FBS as well as serum lipid profile in STZ- NA diabetes-induced rat. Also, it results in an increase in their weight gain.

**Keywords:** *Cuminum cyminum*, diabetic, *Lactobacillus plantarum* A7, soy milk

### Introduction

Diabetes is a prevalent chronic disease accompanied by long-term damage, dysfunction, and failure of different organs, particularly the eyes, kidneys, nerves, heart, and blood vessels.<sup>[1]</sup> An increasing aged population, urbanization, sedentary lifestyle and poor nutrition, as well as a rising level of obesity, are significant factors contributing to the rapid increase in the prevalence of diabetes all over the world, particularly among people in developing countries.<sup>[2]</sup> Moreover, diabetes imposes a substantial economic burden on the health care system in global communities.<sup>[3]</sup> Indeed, research on the control and prevention of diabetes is seriously in need.

Based on recent studies in the field, bioactive ingredients in soy milk can help protect against diabetes,<sup>[4]</sup> whereby soy milk consumption was associated with greater

glycemic control, regulation of insulin and increased insulin sensitivity.<sup>[5]</sup> Soy milk consumption showed beneficial effects in reducing D-dimer (a fibrin degradation product) as one of the coagulation factors in diabetic patients with nephropathy was linked with soy milk consumption.<sup>[6]</sup>

Soy proteins, along with soy isoflavones, have been shown to have a potential role in reducing some atherogenic lipid and lipoprotein serum levels.<sup>[7]</sup> Since soy milk fermentation increases the bioavailability of its isoflavones, beneficial effects of the fermented product are higher than those of the unfermented product.<sup>[8]</sup> Fermentation is also deemed to be a likely factor affecting the ability of soy milk to regulate the effect on lipid metabolism gene expression.<sup>[9]</sup> In particular, fermented products with probiotic bacteria could alleviate the diabetic side effects, risk factors, and complications.<sup>[10]</sup>

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: [reprints@medknow.com](mailto:reprints@medknow.com)

**How to cite this article:** Babashahi M, Mirlohi M, Ghasvand R, Azadbakht L, Mosharaf L, Torki-Baghdadorani S. Effects of probiotic soy milk fermented by *Lactobacillus plantarum* A7 (KC 355240) added with *Cuminum cyminum* essential oil on fasting blood glucose levels, serum lipid profile and body weight in diabetic Wistar rats. *Int J Prev Med* 2020;11:8.

Mina Babashahi,  
Maryam Mirlohi<sup>1</sup>,  
Reza Ghasvand<sup>2</sup>,  
Leila Azadbakht<sup>2</sup>,  
Laleh Mosharaf<sup>3</sup>,  
Sahar  
Torki-Baghdadorani<sup>1</sup>

Student Research Committee, School of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran, <sup>1</sup>Food Security Research Center and Department of Food Sciences and Technology, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran, <sup>2</sup>Food Security Research Center and Department of Community Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran, <sup>3</sup>Agricultural Engineering Research Department, Isfahan Center for the Research of Agricultural Science and Natural Resources, Isfahan, Iran

**Address for correspondence:**  
Dr. Maryam Mirlohi,  
Food Security Research Center  
and Department of Food  
Sciences and Technology, School  
of Nutrition and Food Sciences,  
Isfahan University of Medical  
Sciences, Isfahan, Iran.  
E-mail: [m\\_mirlohi@hlth.mui.ac.ir](mailto:m_mirlohi@hlth.mui.ac.ir)

### Access this article online

**Website:**  
[www.ijpvmjournal.net/www.ijpvm.ir](http://www.ijpvmjournal.net/www.ijpvm.ir)

**DOI:**  
10.4103/ijpvm.IJPVM\_541\_17

### Quick Response Code:



Probiotics are dietary supplements that, inadequate number, could modulate the activity of specific molecular pathways.<sup>[11]</sup>

*Cuminum cyminum* is an aromatic plant that is part of the *Apiaceae* family. Apart from its several usages in food products around the world, it has many applications in traditional herbal medicine to treat diseases including diabetes mellitus, dyspepsia and spasmodic gastrointestinal and inflammatory disorders.<sup>[12]</sup> Aqueous extract of *C. cyminum* has reduced risk factors associated with atherosclerosis, including high levels of cholesterol in plasma and had preventive effects on the body weight reduction in diabetic rats.<sup>[13]</sup> Also, methanolic extract of *C. cyminum* seed was capable of modulating blood glucose in diabetic rats.<sup>[14]</sup>

Although the positive effects of probiotic soy milk or *C. cyminum* in diabetes management were previously indicated, the impact of their combination has not been considered so far. The present study evaluates the effects of probiotic soy milk fermented by LA7 added with essential oil of *C. cyminum* on fasting blood glucose (FBS), serum lipid profiles and body weight in streptozotocin-nicotinamide-induced diabetic rats.

## Methods

### Soy milk samples

In the present study, four types of soy milk samples were prepared. Pasteurized plain soy milk was bought from Shir Soya Esfahan Company in Iran. The second type of soy milk samples was made by fermentation of the plain soy milk with *Lactobacillus plantarum* A7 (KC 355240, LA7) which was obtained from the food microbiology laboratory, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. Overnight cultures were prepared using 1% inoculums in de-Man–Rogosa broth (MRS) (Merck-Germany) and aerobically incubated at 37°C for 24 h (Irakhodsaz, Iran). Active bacteria were achieved through two successive overnight cultures. A bacterial pellet was obtained by three-step centrifugation at 6000, 8000, 10000 rpm, each lasting for 15 min (Seurita-B. Braun, Hamburg, Germany), followed by washing with normal saline. The bacterial sediment was suspended and diluted with a physiological serum to reach 0.5 optical density (OD) at 620 (λ) wave length determined by a spectrophotometer (Jenway-UK). Each flask containing soy milk (200 ml) was mixed with 1% (v/v) of the active culture, and the cultured samples underwent fermentation at 37°C in aerobic conditions. The third soy milk fortified with plant extract was made using the plain soy milk mixed with 0.02% (v/v) essential oil of *C. cyminum* (Barij Essence Pharmaceutical Company, Iran). Our previous study on the growth of LA7 in soy milk containing essential oil of *C. cyminum* revealed that cell numbers of LA7 can achieve 10<sup>9</sup> CFU/ml in the presence of

0.02% (v/v) of the given essential oil after 9 h fermentation. The same procedure was employed in the preparation of the fourth soy milk group in the present study.<sup>[15]</sup>

### Animals

16-week-old male Wistar rats weighing 185 ± 25 g raised in the animal house of Isfahan School of Pharmacy and Pharmaceutical Sciences were used. The rats were housed five per cage under standard conditions, including ambient temperature (22 ± 2°C) at 45-55% relative humidity, 12h each of dark and light cycle, and fed a standard pellet rat diet [Table 1] (Behparvar Company, Tehran, Iran), with free access to water.

### Streptozotocin-nicotinamide-induced diabetic rats

Diabetes was induced in overnight-fasted rats by administering a single intraperitoneal injection of freshly prepared streptozotocin (STZ) (Sigma Aldrich Company, Germany) at 50 mg/kg bw; subsequently, after 15 min 100 mg/kg of nicotinamide (NA) (Sigma Aldrich Company, Germany) in 0.1 M citrate buffer (pH = 4.5)<sup>[16,17]</sup> was injected to each rat. Diabetes was confirmed in the STZ-NA treated rats by measuring FBS levels after one week of induction. Rats with FBS greater than 200 mg/dl were considered diabetic.<sup>[16]</sup> Then the rats were randomly divided into five separate groups (*n* = 10 each): of Control group (C group), Soy milk group (SM group), Probiotic soy milk group (PSM group), Soy milk containing essential oil of *C. cyminum* group (SMC group) and Probiotic soy milk containing essential oil of *C. cyminum* group (PSMC group). The study was carried out in accordance with the guidelines of the Research Ethics Committee for animal experiments set forth by Isfahan University of Medical Sciences, Isfahan, Iran.

### Experimental design

During the one-month study period, the C, SM, PSM, SMC, PSMC groups of rats were respectively gavaged

**Table 1: The content of the standard pellet rat diet\***

Content	Percent**
Protein	19.5-20.5
Fat	3.5-4.5
Fiber	4-4.5
Ashe	Maximum 10
Calcium	0.95-1
Phosphorus	0.65-0.7
Salt	0.5-0.55
Moisture	Maximum 10
Lysine	1.15
Methionine	0.33
Threonine	0.72
Tryptophan	0.25
Energy	16.16-17

\*Declared by producer: Behparvar Company, Tehran, Iran. \*\*Data presented in ranges show minimum and maximum values

1 ml/day of physiological saline, plain soy milk, probiotic soy milk, soy milk containing essential oil of *C. cyminum* and probiotic soy milk containing essential oil of *C. cyminum* samples. Blood samples were collected using a microcapillary tube from orbital sinus plexus under light ether anesthesia after overnight starvation<sup>17</sup> on the 1<sup>st</sup>, 10<sup>th</sup>, 20<sup>th</sup> and 30<sup>th</sup> days of the study. FBS (mg/dl) was measured using a glucometer (Easy Gluco™, Berlin, Germany). For analysis of blood lipids, serum was obtained through 20-min centrifugation at 3000 rpm and stored in a freezer at - 80°C until analysis. TC (mg/dl), TG (mg/dl), HDL-C (mg/dl) and LDL-C (mg/dl) concentrations were determined by using a commercial kit (Biosystems, Spain) on an A<sub>15</sub>-Autoanalyser set (Biosystems, Barcelona, Spain). The body weight of rats was measured at 10-day intervals (Sartoruse balance, Germany). For insurance of probiotic replacement, the fecal samples were collected from C, SM and PSM groups on the 1<sup>st</sup>, 15<sup>th</sup> and 30<sup>th</sup> days of the experiment. The population of *Lactobacilli* was calculated by using the pour plate count method on MRS agar and incubated anaerobically under 5% CO<sub>2</sub> at 37°C for 48 h (BioTek Instruments Inc., USA).

### Statistical analyses

The data are represented as the mean ± standard error of the mean. The statistical analysis was performed using IBM SPSS Statistics version 20. The formula also calculated the percent change for each variable  $(E - B)/B \times 100$ , where E is the 'end of treatment' values and B is the baseline values. Between-group comparison of percent change values was done by one-way analysis of variance (ANOVA) followed by post-hoc LSD multiple range tests. Repeated measures ANOVA was used to compare the mean values within groups at different measurement times. Also, this statistical test (repeated measures ANOVA) was used to examine interaction effects of group and time on the FBS, TC, TG, LDL-C and HDL-C. Differences with  $P < 0.05$  were considered significant.

### Results

The mean values of FBS, TC, TG, LDL-C and HDL-C and the corresponding percent changes in all studied groups during the study period were presented in Table 2. Since the baseline for some studied factors was indicated to be relatively different between the groups, the mean comparison analysis was carried out on the mean percent changes for all the studied factors in addition to the average raw data obtained in every sampling time interval (10<sup>th</sup>, 20<sup>th</sup> and 30<sup>th</sup> days of intervention).

#### Changes in FBS levels

As shown in Table 2, the results of the one-way ANOVA analysis showed that percent change values of FBS in the studied groups related to the all times are significantly different ( $P < 0.05$ ). The findings of the repeated measures ANOVA test showed that mean values of this parameter (FBS) in different times of all studied groups are

significantly different ( $P < 0.0001$ ). In addition, interaction effects of group and time represented a significant impact on the FBS ( $P = 0.01$ ).

FBS levels decrease over time in all conditions compared to baseline, except for control. Just after 10 days of the intervention, a significant decrease in FBS in all treated groups was revealed compared to the control group, and this trend continued to the 20<sup>th</sup> day of the study ( $P < 0.05$ ). However, at the end of the experiment, PSM and PSMC showed the most reducing percent change in serum blood glucose ( $-48.16 \pm 9.53\%$  and  $-49.93 \pm 2.81\%$ , respectively), suggesting that concerning blood glucose reduction, probiotic inclusion was even more effective than the used extract.

#### Changes in TG levels

Based on the one-way ANOVA analysis in Table 2, there was not a significant difference in percent change values of TG in the studied groups related to the all times ( $P > 0.05$ ). The repeated measures ANOVA test revealed that mean values of TG in different times of all studied groups are significantly different ( $P < 0.05$ ). Furthermore, interaction effects of group and time demonstrated a significant impact on the TG ( $P = 0.008$ ).

Regarding the change in TG, among the studied rat groups, PSMC exhibited a rapid, significant reduction in TG after ten days of the study, and the occurred difference this parameter with other groups remained steady all through the study period ( $P < 0.05$ ). At the end of the study, although, all the interventions showed significant downward TC values than the control group ( $P < 0.05$ ), comparison of the percent changes in these parameters limited the active treatment to just PSMC ( $-43.44 \pm 9.89\%$ ).

#### Serum TC changes

In Table 2, one-way ANOVA analysis revealed that percent change values of TC in the studied groups related to the all times are not significantly different ( $P > 0.05$ ). On the other hand, the findings of the repeated measures ANOVA test showed that mean values of this parameter (TC) in different times of all studied groups are significantly different ( $P < 0.05$ ). The interaction effects analysis of the group and time revealed a not significant impact on the TG ( $P = 0.636$ ).

As one can see in Table 2, the difference in TC levels followed the same trend as TG. Nevertheless, the significant variations occurred at a later time; after 20 days of study TC levels in the SMC and PSMC groups showed substantial reductions compared with the TC level at baseline ( $P < 0.05$ ). At the end of the intervention, the highest percent change in TC level was observed in the PSMC group ( $24.64 \pm 4.36\%$ ), which was significantly different from the control group ( $P < 0.05$ ).

**Table 2: Serum levels of biochemical parameters in the treatment groups at 10 day intervals**

Biochemical factors	Group	Baseline	10 <sup>th</sup> day of intervention	Percent change <sup>#</sup> in 10 days	20 <sup>th</sup> day of intervention	Percent change <sup>#</sup> in 20 days	30 <sup>th</sup> day of intervention	Percent change <sup>#</sup> in 30 days	P <sub>time</sub> <sup>‡</sup>	P <sub>group</sub> <sup>‡</sup>	P <sub>time*group</sub> <sup>‡</sup>
FBS (mg/dl)	C	340.7±37.76	367.6±41.64	7.98±4.91	400.6±49.13	16.81±6.27	417.1±46.27	23.76±7.62	<0.0001	<0.05	0.01
	SM	273.9±32.85	236.9±25.35 <sup>a</sup>	-10.90±4.44 <sup>a</sup>	190.2±22.1 <sup>a*</sup>	-24.32±8.61 <sup>a</sup>	198.9±19.62 <sup>a*</sup>	-20.69±7.81 <sup>a</sup>			
	PSM	400±71.61	299.16±51.59	-23.06±6.76 <sup>a</sup>	224.66±41.14 <sup>a*</sup>	-32.27±10.30 <sup>a</sup>	184.66±35.05 <sup>a*</sup>	-48.16±9.53 <sup>ab</sup>			
	SMC	368±58.31	301.55±42.44	-14.64±7.00 <sup>a</sup>	272.33±38.12 <sup>a</sup>	-21.11±8.07 <sup>a</sup>	239±34.2 <sup>a*</sup>	-29.38±9.21 <sup>a</sup>			
	PSMC	378±37.94	306.37±33.61	-18.87±2.45 <sup>a</sup>	270.12±37.35 <sup>a*</sup>	-29.57±3.36 <sup>a</sup>	184.12±14.97 <sup>a**†</sup>	-49.93±2.81 <sup>ab</sup>			
TG (mg/dl)	C	109.44±12.46	125.89±14.86	14.03±4.50	134.55±15.81	22.30±5.13	142.78±16.14	27.83±5.59	<0.05	>0.05	0.008
	SM	127.55±18.97	106.44±17.06	-18.04±4.31 <sup>a</sup>	93.22±13.62 <sup>a</sup>	-23.95±6.34 <sup>a</sup>	97.55±9.31 <sup>a</sup>	-6.73±11.87			
	PSM	139.33±23.38	130.33±27.89	4.43±22.89	120±24.16	4.71±32.06	79.66±5.69 <sup>a</sup>	-18.54±32.8			
	SMC	107.78±12.82	108.44±9	8.63±11.03	99.22±5.46	3.71±13.34	91.89±12.88 <sup>a</sup>	-12.67±23.74			
	PSMC	119.87±15.25	85.75±7.49	-26.14±4.05 <sup>ac</sup>	77.87±8.98 <sup>a</sup>	-32.06±7.14 <sup>a</sup>	62.5±10.29 <sup>ab*</sup>	-43.44±9.89 <sup>a</sup>			
TC (mg/dl)	C	70.14±3.76	73.79±6.83	4.27±6.12	72.57±9.54	6.06±16.67	75.14±7.51	7.53±10.1	<0.05	>0.05	0.636
	SM	66.4±5.13	68±2.27	7.83±8.83	59.3±3.07	-4.46±10.49	61.2±3.13 <sup>a</sup>	-0.32±13.22			
	PSM	71±7.97	69.66±6.71	-0.84±2.54	61.33±4.32	-11.30±4.45	59.16±6.38 <sup>a</sup>	-15.84±3.52			
	SMC	74.44±4.2	71.88±4.02	-0.89±7.89	63.88±2.85 <sup>*</sup>	-12.19±5.99	60.77±2.14 <sup>a**†</sup>	-15.89±6.01			
	PSMC	78.37±4.85	71.87±5.04	-7.45±5.46	63.75±3.73 <sup>*</sup>	-17.99±3.6	58.12±2.98 <sup>a**†</sup>	-24.64±4.36 <sup>a</sup>			
LDL-C (mg/dl)	C	14.29±3.11	14.62±2.84	11.48±7.66	15.3±3.08	19.54±11.25	16.68±3.09	28.98±9.32	<0.05	>0.05	0.006
	SM	9.33±1.65	10.16±0.98	31.28±17.99	7.1±0.63 <sup>a</sup>	4.14±25.59	7.2±0.63 <sup>a</sup>	3.18±25.87			
	PSM	15.33±3.96	13.56±3.82	-8.65±12.14 <sup>b</sup>	10.01±4.48	-35.60±17.28 <sup>a</sup>	10.67±4.48 <sup>a</sup>	-35.81±9.7 <sup>a</sup>			
	SMC	8.81±1.07	6.74±1.44 <sup>a</sup>	-27.16±6.93 <sup>ab</sup>	6.58±0.89 <sup>a</sup>	-24.04±6.85	6.12±0.89 <sup>a</sup>	-26.98±10.88 <sup>a</sup>			
	PSMC	13.77±2.76	8.89±1.76	-30.71±9.23 <sup>ab</sup>	7.96±1.61 <sup>a*</sup>	-28.99±11.97 <sup>b</sup>	8.31±1.61 <sup>a*</sup>	-31.26±12.36 <sup>a</sup>			
HDL-C (mg/dl)	C	31.83±2.44	31.87±1.84	1.02±2.95	30.86±2.15	-2.68±2.24	31.68±1.05	-5.97±5.78	<0.0001	>0.05	0.02
	SM	30.71±3.33	34.23±2.13	16.18±8.69	32.14±1.89	9.03±7.76	33.33±2.5	12.59±8.59			
	PSM	32.66±2.44	38.38±1.87 <sup>ac</sup>	20.71±11.05	39.48±2.14 <sup>abd*</sup>	22.50±6.31	41.71±2.45 <sup>ab*</sup>	28.9±5.61 <sup>a</sup>			
	SMC	32±1.75	33.2±1.47	4.68±3.97	35.34±1.54	11.31±3.51	36.99±1.09 <sup>*</sup>	17.51±5.07			
	PSMC	28.91±2.58	35.29±1.65 <sup>*</sup>	30.24±15.17 <sup>a</sup>	33.77±1.81	25.37±15.88 <sup>a</sup>	38.26±1.94 <sup>*</sup>	40.08±14.39 <sup>ab</sup>			

C=Control; SM=Soy milk; PSM=Probiotic soy milk; SMC=Soy milk containing essential oil of *C. cyminum*; PSMC=Probiotic soy milk containing essential oil of *C. cyminum*. Values are presented as Mean±SEM. #Percent change is calculated relative to baseline. One-way ANOVA: <sup>a</sup>P<0.05 vs. control in the same columns; <sup>b</sup>P<0.05 vs. SM in the same columns; <sup>c</sup>P<0.05 vs. SMC group in the same columns; <sup>d</sup>P<0.05 vs. PSMC group in the same columns. Repeated measures ANOVA: \* P<0.05 vs. baseline in the same row; † P<0.05 vs. after 10 days of intervention in the same row; ‡P<sub>time</sub><sup>c</sup> and P<sub>group</sub><sup>c</sup>: Fixed factor; ‡P<sub>time\*group</sub><sup>c</sup>: Interaction effect



### Changes in serum LDL-C

One-way ANOVA analysis depicts that percent change values of LDL-C in the studied groups related to the all times were not significantly different ( $P > 0.05$ ) [Table 2]. The repeated measures ANOVA test revealed that the mean values of LDL-C in different times of all studied groups are significantly different ( $P < 0.05$ ). Furthermore, interaction effects of group and time revealed a significant impact on the LDL-C ( $P = 0.006$ ).

Concerning the LDL-C level, all the four treated groups achieved improvement throughout the study. However, meaningful differences were observed in the groups that received mixed formulations in that soon after ten days of intervention, PSM, SMC, and PSMC indicated reduced LDL-C in comparison to the control and SM group. Interestingly, at the end of the study, with the highest percent changes which was observed in the PSM group ( $-35.81 \pm 9.7\%$ ), PSMC, SMC, and PSM groups significantly showed less LDL-C level as compared with the control group ( $P < 0.05$ ). While the intake of plain soy milk in the SM group failed to impose such a reduction.

### Changes in serum HDL-C

As shown in Table 2, the result of the one-way ANOVA analysis demonstrated that percent change values of HDL-C in the studied groups related to the all times are not significantly different ( $P > 0.05$ ). In addition, the findings of the repeated measures ANOVA test showed that mean values of this parameter (HDL-C) in different times of all studied groups are significantly different ( $P < 0.0001$ ). In addition, interaction effects of group and time depicted a significant impact on the HDL-C ( $P = 0.02$ ).

As depicted in Table 2, during the study, all study groups, except control showed a rise in HDL-C in a way that at the end of the intervention, three of the four treated groups including PSM, SMC and PSMC showed significant changes in HDL-C from the baseline ( $P < 0.05$ ). However, comparing the groups, PSM and PSMC revealed the most effective treatments. HDL-C percent changes levels of the PSMC group were different compared with that in control all through the study time. Also, at the end of the experiment, with the highest HDL-C percent change value, this group was different compared with that of SM groups either ( $40.08 \pm 14.39\%$  vs.  $12.59 \pm 8.59\%$ ).

### Changes in body weight

Figure 1 shows the weight of the rats during the experiment. The body weight in the PSMC group was different from the control group after ten days of the experiment. These differences were also observed at the end of the experiment. Also at this time, there was a significant difference between the weight of the SM and PSM groups ( $P < 0.05$ ). The weight of the SMC group was different from the control group after 20 days of intervention. At the end of the experiment, the weight of the PSM, SMC, and PSMC groups was different from the baseline. In terms of percent changes, all groups were different from the C group (C =  $1.28 \pm 5.46\%$ ; SM =  $12.27 \pm 5.38\%$ ; PSM =  $28.22 \pm 5.83\%$ ; SMC =  $20.04 \pm 7.32\%$ ; PSMC =  $29.46 \pm 2.82\%$ ), and the weight of the PSMC group differed from the SM group. The greatest percent change was observed in the PSMC group ( $29.46 \pm 2.82\%$ ).

### Changes in fecal Lactobacilli

Based on the one-way ANOVA analysis in Table 3, there was a significant difference in percent change values of fecal Lactobacilli in the studied groups related to the all times ( $P < 0.0001$ ). The repeated measures ANOVA test revealed that mean values of fecal Lactobacilli in different times of all studied groups are significantly different ( $P < 0.0001$ ). Furthermore, interaction effects of group and time demonstrated a significant impact on the fecal Lactobacilli ( $P < 0.0001$ ).

Table 3 reports the number of fecal Lactobacilli. After 15 days of intervention, the number of fecal Lactobacilli




Figure 1: Body weight (g) in the treatment groups at 10 day intervals. C = Control; SM = Soy milk; PSM = Probiotic soy milk; SMC = Soy milk containing essential oil of *C. cyminum*; PSMC = Probiotic soy milk containing essential oil of *C. cyminum*. Values are presented as Mean  $\pm$  SEM. <sup>a</sup> $P < 0.05$  vs. control in the same time. <sup>b</sup> $P < 0.05$  vs. SM group in the same time. <sup>c</sup> $P < 0.05$  vs. PSM group in the same time. <sup>\*</sup> $P < 0.05$  vs. baseline in the same group

Table 3: Faecal lactobacilli counts (Log cfu/g) in the treatment groups at 15 day intervals

Group	Baseline	15 <sup>th</sup> day of intervention	30 <sup>th</sup> day of intervention	Percent change	$P_{time}^{\ddagger}$	$P_{group}^{\ddagger}$	$P_{time*group}^{\ddagger}$
C	8.61 $\pm$ 0.18	8.40 $\pm$ 0.19	8.48 $\pm$ 0.11	-1.22 $\pm$ 1.51	<0.0001	<0.0001	<0.0001
SM	8.46 $\pm$ 0.17	8.38 $\pm$ 0.17	8.61 $\pm$ 0.12	1.92 $\pm$ 1.61			
PSM	8.85 $\pm$ 0.29	9.59 $\pm$ 0.27 <sup>ab</sup>	10.81 $\pm$ 0.25 <sup>ab*†</sup>	22.47 $\pm$ 6.40 <sup>ab</sup>			

C=Control; SM=Soy milk; PSM=Probiotic soy milk. Values are presented as Mean $\pm$ SEM. One-way ANOVA: <sup>a</sup> $P < 0.05$  vs. control in the same columns; <sup>b</sup> $P < 0.05$  vs. SM group in the same columns. Repeated measures ANOVA: <sup>\*</sup> $P < 0.05$  vs. baseline in the same row; <sup>†</sup> $P < 0.05$  vs. after 15 days of intervention in the same row; <sup>‡</sup> $P_{time}$ , and  $P_{group}$ : Fixed factor; <sup>‡</sup> $P_{time*group}$ : Interaction effect

in the PSM group was different from the control and SM group. This difference was also observed at the end of the intervention. In this time, *Lactobacilli* counts in the PSM group were different compared with pre-intervention and at 15 days. The highest percent change in the number of bacteria was observed in the PSM group ( $22.47 \pm 6.40\%$ ), which was also different from the other two groups.

## Discussion

The findings of the present study showed that all applied treatments were to some extent beneficial to the serum blood parameters of STZ-induced diabetic rats during one month. However, the supposition of this study has been confirmed in that fermented soy milk, added with *C. cuminum* extract is more effective than each of the treatments.

In Table 4, the results of the most similar animal studies to the present work are summarized. SM group revealed improvement in blood glucose and TG in comparison with the control group. These results are consistent with the results of Tsai *et al.* in that in obese subjects with type 2 diabetes, soy polysaccharide significantly managed postprandial serum glucose concentrations and TG levels.<sup>[18]</sup> The regulatory effects of soy milk products on FBS and serum lipid parameters were associated with its flavones, genistein, protein and polysaccharides.<sup>[18-21]</sup>

In another study, Rossi showed soy milk consumption by hypercholesterolemic rabbits increased HDL-C levels, while, this effect was not observed in the SM group in our study.<sup>[22]</sup>

Several mechanisms are suggested to bear advantages of soy component to diabetes subjects; inhibition of intestinal glucose uptake via a reduction in sodium-dependent glucose transporter, and beta-cell secretion promotion leading to a reduction in postprandial hyperglycemia.<sup>[23]</sup> The isolated soy protein was found to be able to decrease the expression of sterol regulatory element-binding protein binding (SREBP), followed by increased adiponectin levels and reduced triglyceride levels.<sup>[9]</sup> Also, soy peptides expression of LDL-C receptors in the liver is referred for decreased levels of serum cholesterol.<sup>[24]</sup>

Soy milk isoflavones can regulate glucose and lipid metabolism through the regulation of gene expression related to nuclear receptors of peroxisome proliferator-activated receptor (PPAR), increases in lipoprotein clearance and HDL-C biogenesis.<sup>[9,25]</sup>

Despite the significant difference of weight in SM group compared to control which appeared clearly at the end of the study, this group did not put weight from their baseline. Administration of nutritious soy milk in the treated groups provided them with the additional source of energy that resulted in their weight gain in comparison to the control group. Protein supply was mentioned to be responsible for weight gain in STZ-diabetic rats receiving soy milk.<sup>[26]</sup>

The effects of soy consumption on body weight changes are controversial. While soy milk played a role in the regulation of body weight through increasing energy expenditure in male rats<sup>[27]</sup> and phytoestrogen content of soy reduced fat accumulation,<sup>[28]</sup> It was reported that isoflavones in soy milk improved metabolism in diabetic rats and led to their weight gain. Meanwhile, a human study published on the ineffectiveness of soy protein daily intake on body weight changes.<sup>[29]</sup>

Using soymilk-containing probiotic bacteria usually brings up enhanced beneficial effects on blood glucose and serum lipid parameters compared to soymilk.

Inconsistent to our results, using a diabetes animal model induced with streptozotocin, Mrraza indicated that the fermented soymilk with *Lactobacillus rhamnosus* CRL981 gave rise to more reduction in blood glucose levels than unfermented soymilk.<sup>[10]</sup>

Regarding percent change in serum lipid parameters, comparison of PSM with SM group showed no superiority of the fermented product. This is consistent with the results of the two other studies<sup>[10,30]</sup> in that, fermented soy milk induced no more significant difference on the lipid parameters of STZ-diabetic rats than the plain soy milk.

*Lactobacillus plantarum* A7 (KC 355240) is a native strain with proven probiotic properties.<sup>[31,32]</sup> In our previous study, this strain of bacteria has the potential to decrease serum TC, LDL-C, and TG in mice.<sup>[31]</sup> It was reported that soy milk fermented with another *L. plantarum* strain, *Lactobacillus plantarum* P-8, produced a regulation effect in serum lipid profile hyperlipidemic rats.<sup>[33]</sup> Probiotic bacteria have hypolipidaemic effects by several probable mechanisms<sup>[34]</sup> and some studies, confirmed the positive physiological function of *Lactobacillus* strains belonging to, *L. plantarum* species. Xie *et al.* study showed that supplementation of *Lactobacillus plantarum* 9-41-A and *Lactobacillus fermentum* M1-16 had beneficial effects on TG, TC and LDL-C in serum, enhancing effects on intestinal *Lactobacillus* and *Bifidobacterium* bacteria and reductions in body weight in rats fed a high cholesterol diet.<sup>[35]</sup>

In our study, examination of fecal samples of the control group, SM and PSM were carried out to investigate the activity and efficiency of cultured bacteria in the PSM group. The result showed that PSM group had the highest number of lactobacilli in feces, suggesting that probiotic microorganism replacement promotes *Lactobacilli* growth in the rat intestine.

Despite a great deal of evidence on the effects of fermented soy milk on glucose metabolism,<sup>[5,10]</sup> using a combination of fermented soymilk with a natural ingredient was rarely investigated. Ju and Han showed the hypoglycemic effect of fermented soymilk extracts added with 5%

**Table 4: Animal studies in which soy components, soymilk, fermented soymilk or Cuminum cyminum were used as dietary supplements for diabetes management in animal models**

Author	Animal model	Compound	Amount and duration	Fasting blood glucose*	TG*	TC*	LDL-C*	HDL-C*	Body weight*	Reference
Lu et al.	Diabetic-STZ rats	high-isoflavone soy protein	20%/For 8 weeks	Significantly decreased	ND	ND	ND	Significantly increased	Significantly increased	21
Lee et al.	Diabetic-STZ rats	genistein supplement	600 mg/kg diet/For 3 weeks	Significantly decreased	Significantly decreased	Significantly decreased	Significantly decreased	Significantly increased	Significantly ND	19
		isolated soy protein supplement	200 g/kg /For 3 weeks	Significantly decreased	Significantly decreased	Significantly decreased	Significantly decreased	Significantly increased	Significantly ND	
Marazza et al.	Diabetic-STZ mice	soymilk	5 ml/day/For 28 day	Significantly decreased	Significantly decreased	Significantly decreased	Significantly decreased	No effect	Significantly increased	10
		soymilk fermented with Lactobacillus rhamnosus CRL981	5 ml/day/For 28 day	Significantly decreased	Significantly decreased	Significantly decreased	Significantly decreased	No effect	Significantly increased	
Mohammadi Sartang et al.	Diabetic-STZ rats	Soymilk	1 mL/day/For 28 days	Significantly decreased	Significantly decreased	Significantly decreased	No effect	Significantly increased	Significantly increased +	30
		fermented soymilk (by <i>Bifidobacterium lactis</i> )	1 mL/day/For 28 days	Significantly decreased	Significantly decreased	Significantly decreased	No effect	Significantly increased	Significantly increased +	
		fermented soymilk fortified with omega-3	1 mL/day/For 28 days	Significantly decreased	Significantly decreased	Significantly decreased	No effect	Significantly increased	Significantly increased +	
Willatgamuwa et al.	Diabetic-STZ rats	Cumin powder	1.25% of diet/For 8 weeks	Significantly decreased	ND	ND	ND	ND	A slight increasing	40
Jagtap et al.	Diabetic-STZ rats	Methanolic extract of seeds of <i>C. cyminum</i>	200 mg/day/For 28 days	Significantly decreased	ND	ND	ND	ND	Significantly increased	14
		Methanolic extract of seeds of <i>C. cyminum</i>	400 mg/day/For 28 days	Significantly decreased	ND	ND	ND	ND	Significantly increased	
		Methanolic extract of seeds of <i>C. cyminum</i>	600 mg/day/For 28 days	Significantly decreased	ND	ND	ND	ND	Significantly increased	
Srivastava et al.	High fructose fed diabetic-STZ rats.	Ethanolic extract of seeds of <i>C. cyminum</i>	250 mg/Kg body weight/For 14 days	Significantly decreased	Significantly decreased	Significantly decreased	Significantly decreased	Significantly increased +	Significantly ND	37
Present study	Diabetic STZ-NA rats	SM	1 ml/day/For one month	Significantly decreased	Significantly decreased	Significantly decreased	Significantly decreased	Significantly increased +	Significantly increased +	-
		PSM	1 ml/day/For one month	Significantly decreased	Significantly decreased	Significantly decreased	Significantly decreased	Significantly increased +	Significantly increased +	

Contd...

**Table 4: Contd...**

Author	Animal model	Compound	Amount and duration	Fasting blood glucose*	TG*	TC*	LDL-C*	HDL-C*	Body weight*	Reference
	SMC		1 ml/day/For one month	Significantly decreased -53.14	-40.5	-23.47	Significantly decreased -58.96	+23.48	Significantly increased + 18.76	
	PSMC		1 ml/day/For one month	Significantly decreased -73.69	Significantly decreased -71.27	Significantly decreased -32.17	Significantly decreased -60.24	Significantly increased + 46.05	Significantly increased + 28.18	

C=Control; SM=Soy milk; PSM=Probiotic soy milk; SMC=Soy milk containing essential oil of *C. cyminum*; PSMC=Probiotic soy milk containing essential oil of *C. cyminum*; ND=Not determined; \*Comparison with the diabetic control group; \*\*Percent change compared to the diabetic control group.

bokbunja (FSB) in STZ-induced diabetic mice. Although their study was different from us in design, we share a common conclusion of the superior effects of the combined formula of fermented soy milk with a natural ingredient.<sup>[5]</sup> In another study carried out by Mohammadi Sartang *et al.*, the addition of omega three oil to fermented soy milk did not produce extra beneficial effects on serum blood glucose and lipid.<sup>[30]</sup>

Our results concerning soy milk with *C. cyminum* (SMC), showed that this treatment had an advantage over the FBS and LDL-C of the tested STZ-diabetic rats.

The effect of 5% cumin powder on blood glucose levels resulted in a 17% reduction in the treated STZ-induced group than STZ-control in one study.<sup>[36]</sup> In two other studies, administration 200-600 mg/kg metabolic extract *C. cyminum* seeds in STZ rats caused 17- 60% reduction in blood glucose from the control group.<sup>[14,37]</sup> Using approximately 200 mg extract per kg of soymilk, 50% reduction of fasting blood sugar from the control group in our study supports other studies results [Table 4]. The beneficial effect of *C. Cyminum* on serum blood lipid parameters was also examined. Although, our results confirmed the efficiency of *C. cyminum* on these parameters for FBS and LDL-C, The significance of the results obtained by this group is that as a control to the fermented product (PSMC), this treatment includes innate potential which enhanced through fermentation. The same reason can be given for using fermented soy milk with identified beneficial effects which were a plant extract free control to PSMC. This treatment showed superior effect than other therapies for managing diabetes complications. Meanwhile, the results from the body weight data showed that PSMC group was more effective in weight gain than the other groups. This is a limitation of our study that after treating the rats with STZ, their weight loss was not recorded. In doing so, the increase in weight in the treated groups could have cleared that this defect was controlled by applied treatments. Marazza *et al.* concluded that treating the STZ induced mice with soymilk fermented with *L. rhamnosus* CRL981 prevented the weight loss that appeared in the diabetic control group.<sup>[10]</sup> Weight loss in diabetes-induced rats was associated with dehydration, loss of body fat and protein catabolism caused by increased catabolic reactions.<sup>[38-40]</sup>

### Conclusions

Probiotic soy milk using LA7 added with essential oil of *C. cyminum* create a more significant reduction in FBS, TG and TC levels, enhances HDL-C levels and has beneficial effects on weight gain in comparison with probiotic soy milk and soy milk containing *C. cyminum* essential oil in diabetic rats. Besides, PSMC decreased LDL-C levels. It seems that the combination of probiotics and essential oils is a robust functional supplement for diabetes management in an animal model.



## Acknowledgments

The authors would like to thank the staff of Food Security Research Center for their financial support. They are also grateful to Mrs. Marziyeh Aghababaei and Parastoo Tavassoli for their assistance in this project. This study was approved by the School of Nutrition and Food Sciences, Isfahan University of Medical Sciences (code 293112).

## Financial support and sponsorship

This study was conducted as an MSc research thesis (code 293112, approval date: 27 December 2015), ethically assessed and approved by research ethics board acting under the graduate office at the Isfahan University of Medical Sciences.

## Conflicts of interest

There are no conflicts of interest.

**Received:** 16 Dec 17 **Accepted:** 08 Aug 19

**Published:** 24 Jan 20

## References

- American diabetes association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2014;37:81-90.
- Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J. Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes Res Clin Pract* 2014;103:137-49.
- Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, *et al.* Global healthcare expenditure on diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010;87:293-301.
- Liu ZM, Chen YM, Ho SC. Effects of soy intake on glycemic control: A meta-analysis of randomized controlled trials. *Am J Clin Nutr* 2011;93:1092-101.
- Ju HE, Han JS. Hypoglycemic Effect of Fermented Soymilk Added with Bokbunja (*Rubus coreanus* Miquel) in Diabetic Mice. *Food Sci Biotechnol* 2010;19:1041-6.
- Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. *Am J Clin Nutr* 2005;81:397-408.
- Miraghajani MS, Esmailzadeh A, Najafabadi MM, Mirlohi M, Azadbakht L. Soy milk consumption, inflammation, coagulation, and oxidative stress among type 2 diabetic patients with nephropathy. *Diabetes Care* 2012;35:1981-5.
- Li H, Yan L, Wang J, Zhang Q, Zhou Q, Sun T, *et al.* Fermentation characteristics of six probiotic strains in soymilk. *Ann Microbiol* 2012;62:1473-83.
- Kim Y, Yoon S, Lee SB, Han HW, Oh H, Lee WJ, *et al.* Fermentation of soy milk via *Lactobacillus plantarum* improves dysregulated lipid metabolism in rats on a high cholesterol diet. *PLoS One* 2014;9:e88231.
- Marazza JA, LeBlanc JG, de Giori GS, Garro MS. Soymilk fermented with *Lactobacillus rhamnosus* CRL981 ameliorates hyperglycemia, lipid profiles and increases antioxidant enzyme activities in diabetic mice. *J Funct Foods* 2013;5:1848-53.
- Bomba A, Brandeburova A, Ricanyova J, Strojny L, Chmelarova A, Szabadosova V, *et al.* The role of probiotics and natural bioactive compounds in modulation of the common molecular pathways in pathogenesis of atherosclerosis and cancer. *Biologia* 2012;67:1-13.
- Allahghaderi T, Rasooli I, Owlia P, Jalali-Nadooshan M, Ghazanfari T, Taghizadeh M, *et al.* Antimicrobial property, antioxidant capacity, and cytotoxicity of essential oil from cumin produced in Iran. *J Food Sci* 2010;75:54-61.
- Dhandapani S, Subramanian VR, Rajagopal S, Namasivayam N. Hypolipidemic effect of cuminum cyminum L. on alloxan induced diabetic rats. *Pharmacol Res* 2002;46:251-5.
- Jagtap AG, Patil PB. Antihyperglycemic activity and inhibition of advanced glycation end product formation by *Cuminum cyminum* in streptozotocin induced diabetic rats. *Food Chem Toxicol* 2010;48:2030-6.
- Babashahi M, Mirlohi M, Ghiasvand R, Toriki-Baghdadorani S. Evaluation of response surface methodology to predict optimum growth conditions for *Lactobacillus plantarum* A7 (KC 355240) in probiotic soy milk containing essential oil of *Cuminum cyminum*. *Recent Pat Food Nutr Agric* 2016;8:1-6.
- Chen T, Kagan L, Mager DE. Population pharmacodynamic modeling of exenatide after 2-week treatment in STZ/NA diabetic rats. *J Pharm Sci* 2013;102:3844-51.
- Petchi R, Vijaya C, Parasuraman S. Antidiabetic activity of polyherbal formulation in streptozotocin - nicotinamide induced diabetic wistar rats. *J Tradit Complement Med* 2014;4:108-17.
- Tsai A, Vinik A, Lasichak A, Lo G. Effects of soy polysaccharide on postprandial plasma glucose, insulin, glucagon, pancreatic polypeptide, somatostatin, and triglyceride in obese diabetic patients. *Am J Clin Nutr* 1987;45:596-601.
- Lee JS. Effects of soy protein and genistein on blood glucose, antioxidant enzyme activities, and lipid profile in streptozotocin-induced diabetic rats. *Life Sci* 2006;79:1578-84.
- Bathena SJ, Velasquez MT. Beneficial role of dietary phytoestrogens in obesity and diabetes. *Am J Clin Nutr* 2002;76:1191-201.
- Lu MP, Wang R, Song X, Chibbar R, Wang X, Wu L, *et al.* Dietary soy isoflavones increase insulin secretion and prevent the development of diabetic cataracts in streptozotocin-induced diabetic rats. *Nutr Res* 2008;28:464-71.
- Rossi EA, Vendramini RC, Carlos IZ, Ueiji IS, Squinzari MM, Silva SI Jr, *et al.* Effects of a novel fermented soy product on the serum lipids of hypercholesterolemic rabbits. *Arq Bras Cardiol* 2000;74:213-6.
- Vedavanam K, Srijayanta S, O'Reilly J, Raman A, Wiseman H. Antioxidant action and potential antidiabetic properties of an isoflavonoid-containing soyabean phytochemical extract (SPE). *Phytother Res* 1999;13:601-8.
- Cho SJ, Juillerat MA, Lee CH. Cholesterol lowering mechanism of soybean protein hydrolysate. *J Agric Food Chem* 2007;55:10599-604.
- Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. *J Nutr* 2003;133:1238-43.
- Shim JY, Kim KO, Seo BH, Lee HS. Soybean isoflavone extract improves glucose tolerance and raises the survival rate in streptozotocin-induced diabetic rats. *Nutr Res Pract* 2007;1:266-72.
- Simmen FA, Mercado CP, Zavacki AM, Huang SA, Greenway AD, Kang P, *et al.* Soy protein diet alters expression of hepatic genes regulating fatty acid and thyroid hormone metabolism in the male rat. *J Nutr Biochem* 2010;21:1106-13.
- Cederroth CR, Nef S. Soy, phytoestrogens and metabolism: A review. *Mol Cell Endocrinol* 2009;304:30-42.
- Azadbakht L, Atabak S, Esmailzadeh A. Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 diabetes

- with nephropathy a longitudinal randomized clinical trial. *Diabetes Care* 2008;31:648-54.
30. Mohammadi Sartang M, Mazloomi SM, Tanideh N, Rezaian Zadeh A. The effects of probiotic soymilk fortified with omega-3 on blood glucose, lipid profile, haematological and oxidative stress, and inflammatory parameters in streptozotocin nicotinamide-induced diabetic rats. *J Diabetes Res* 2015;2015:1-9.
  31. Fazeli H, Moshtaghian j, Mirlohi M, Shirzadi M. Reduction in serum lipid parameters by incorporation of a native strain of *Lactobacillus Plantarum* A7 in Mice. *J Diabetes Metab Disord* 2010;9:1-7.
  32. Mirlohi M, Soleimanian Zad S, Dokhani S, Sheikh Zeinodin M. Microbial and physiochemical changes in yoghurts containing different *Lactobacillus delbrueckii* subsp. *bulgaricus* strains in association with *Lactobacillus plantarum* as an adjunct culture. *Int J Dairy Technol* 2014;67:246-54.
  33. Wang Z, Bao Y, Zhang Y, Zhang J, Yao G, Wang S, *et al.* Effect of soymilk fermented with *Lactobacillus plantarum* p-8 on lipid metabolism and fecal microbiota in experimental hyperlipidemic rats. *Food Biophys* 2013;8:43-9.
  34. Salaj R, Stofilova J, Soltesova A, Hertelyova Z, Hijova E, Bertkova I, *et al.* The effects of two *Lactobacillus plantarum* strains on rat lipid metabolism receiving a high fat diet. *Sci World J* 2013;2013:1-7.
  35. Xie N, Cui Y, Yin YN, Zhao X, Yang JW, Wang ZG, *et al.* Effects of two *Lactobacillus* strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet. *BMC Complement Altern Med* 2011;11:1-11.
  36. Kumar PA, Reddy PY, Srinivas P, Reddy GB. Delay of diabetic cataract in rats by the antiglycating potential of cumin through modulation of  $\alpha$ -crystallin chaperone activity. *J Nutr Biochem* 2009;20:553-62.
  37. Srivastava R, Srivastava SP, Jaiswal N, Mishra A, Maurya R, Srivastava AK. Antidiabetic and antidyslipidemic activities of *Cuminum cyminum* L. in validated animal models. *Med Chem Res* 2011;20:1656-66.
  38. Al-Shamaony L, Al-Khazraji SM, Twaij HA. Hypoglycaemic effect of *Artemisia herba alba*. II. Effect of a valuable extract on some blood parameters in diabetic animals. *J Ethnopharmacol* 1994;43:167-71.
  39. Hakim ZS, Patel BK, Goyal RK. Effects of chronic ramipril treatment in streptozotocin-induced diabetic rats. *Indian J Physiol Pharmacol* 1997;41:353-60.
  40. Willatgamuwa SA, Platel K, Saraswathi G, Srinivasan K. Antidiabetic influence of dietary cumin seeds (*Cuminum cyminum*) in streptozotocin induced diabetic rats. *Nutr Res* 1998;18:131-42.